Cancer Advisor

Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...

Published by: Dr William Makis on X.com (May 4, 2026) Edited and Reviewed by: OneDayMD Editorial Team Important Medical Disclaimer This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Repurposed drugs like ivermectin and fenbendazole are not approved by the FDA or any major regulatory body for cancer. Self-medication can cause serious side effects including liver toxicity, drug interactions, or delayed standard care. Always consult a qualified oncologist before considering any off-label protocol. Individual results vary widely and often reflect combined therapies. The case below is anonymized from a publicly shared patient report; outcomes are not guaranteed. The Case Background “Patient C.” is a 54-year-old woman diagnosed in July 2025 with Stage IV lung cancer (publicly described as NSCLC) with soft tissue metastases. The primary tumor measured 6.4 × 5.3 cm with SUVmax 9.5 on PET-CT. She also had intrathorac...

Lung cancer treatment has shifted from a one-size-fits-all chemotherapy model to a molecular decision system , where specific gene mutations determine therapy selection. Among these, the EGFR mutation is one of the most clinically important drivers in non-small cell lung cancer (NSCLC). Most mainstream health sites typically: explain EGFR as a definition list symptoms and general treatments avoid deep decision pathways What they miss: mutation subtype differences resistance evolution logic sequencing of therapies real clinical decision flow This guide explains not just what EGFR is , but how it actually drives real treatment decisions across different stages, mutation types, and resistance patterns . 1. What is EGFR in Lung Cancer? The EGFR (Epidermal Growth Factor Receptor) gene controls signals that regulate: cell growth cell division survival signaling pathways When mutated, EGFR becomes permanently “switched on,” causing uncontrolled tumor growth. In lung cancer, EGFR mutations a...

Cancer treatment is evolving faster than ever. From cutting-edge immunotherapies to AI-driven diagnostics, the discoveries of 2026 are reshaping how clinicians detect, monitor, and treat malignancies. These breakthroughs offer hope for longer survival, improved quality of life, and personalized therapies tailored to each patient. The 2026 American Association of Cancer Research (AACR) Annual Meeting took place in San Diego from April 17-22 and reflected how cancer research continues to evolve. Progress is increasingly driven by how advances across biology, technology, and policy come together to shape how we understand disease, develop new treatments, and bring them into practice. A central theme this year was the continued focus on cancer as more than just a collection of tumor cells. It is shaped by a complex ecosystem — immune cells, surrounding tissue, metabolism, and even the microbiome — all interacting in dynamic ways. Credit:  Statista 1. Immunotherapy: Expanding Beyond Che...

Introduction: Can Low-Dose Naltrexone (LDN) Play a Role in Cancer Treatment? Low-dose naltrexone (LDN) has emerged as one of the most discussed repurposed drugs in integrative oncology—drawing attention from researchers, clinicians, and patients seeking safer, adjunctive cancer therapies. Originally developed as a high-dose medication to treat opioid and alcohol dependence, naltrexone behaves very differently when used at much lower doses (typically 1–5 mg daily), triggering unique biological effects that may influence cancer biology. Unlike conventional chemotherapy, which directly targets rapidly dividing cells, LDN appears to work through indirect mechanisms—modulating the immune system, altering inflammatory pathways, and influencing cellular signaling involved in tumor growth. One of the most studied mechanisms involves the opioid growth factor (OGF)–opioid growth factor receptor (OGFr) axis , a regulatory pathway that plays a key role in controlling cell proliferation. By transie...